Literature DB >> 3590191

Evaluation of cis-diamminedichloroplatinum (II) (cisplatin) neurotoxicity in rats.

P De Koning, J P Neijt, F G Jennekens, W H Gispen.   

Abstract

Cisplatin neurotoxicity was studied in rats by using electrophysiological and functional tests. The drug was injected intraperitoneally two times a week (1 mg/kg) up to a cumulative dose of 19.0 mg/kg body wt. At this dose the H-reflex-related sensory nerve conduction velocity was reduced. After cessation of drug administration, the H-reflex-related sensory nerve conduction velocity slowly improved. The motor nerve conduction velocity remained unaffected throughout the intoxication period and concentric needle investigation showed no signs of denervation. In addition, the sensorimotor response to a noxious stimulus presented locally to the foot sole was not affected by the cisplatin treatment. It is concluded that measurement of H-reflex-related sensory nerve conduction velocity is a useful and accurate tool in the evaluation of cisplatin neurotoxicity in rats.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3590191     DOI: 10.1016/0041-008x(87)90178-5

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  13 in total

1.  Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate.

Authors:  F M Boyle; H R Wheeler; G M Shenfield
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  Cisplatin-induced autonomic neuropathy: does it really exist?

Authors:  W P Vandertop; W B de Vries; N C Notermans; M J Nijsen; D J de Wildt; C A Tulleken; W H Gispen
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

3.  Protective effect of amifostine against cisplatin-induced motor neuropathy in rat.

Authors:  Suayib Yalcin; Gulay Nurlu; Bülent Orhan; Dilara Zeybek; Sevda Müftüoğlu; Banu Sarer; Berna Akkuş Yildirim; Eren Cetin
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

Review 4.  The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.

Authors:  Giulia Donvito; Sara R Nass; Jenny L Wilkerson; Zachary A Curry; Lesley D Schurman; Steven G Kinsey; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

5.  Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy.

Authors:  Anna Dzagnidze; Zaza Katsarava; Julia Makhalova; Bernd Liedert; Min-Suk Yoon; Holger Kaube; Volker Limmroth; Juergen Thomale
Journal:  J Neurosci       Date:  2007-08-29       Impact factor: 6.167

6.  Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766.

Authors:  F P Hamers; C Pette; B Bravenboer; C J Vecht; J P Neijt; W H Gispen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats.

Authors:  G Cavaletti; G Tredici; P Marmiroli; M G Petruccioli; I Barajon; D Fabbrica
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

8.  Erythropoietin against cisplatin-induced peripheral neurotoxicity in rats.

Authors:  Bulent Orhan; Suayib Yalcin; Gulay Nurlu; Dilara Zeybek; Sevda Muftuoglu
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

9.  Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin.

Authors:  D Screnci; H M Er; T W Hambley; P Galettis; W Brouwer; M J McKeage
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions.

Authors:  Rossella Marullo; Erica Werner; Natalya Degtyareva; Bryn Moore; Giuseppe Altavilla; Suresh S Ramalingam; Paul W Doetsch
Journal:  PLoS One       Date:  2013-11-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.